Sector
Cell & Gene Therapy
Discover the early-stage Cell & Gene Therapy ecosystem: investors, accelerators, incubators, fellowships, grants, and global hubs powering next-gen Cell & Gene Therapy startups.
Discover the early-stage Cell & Gene Therapy ecosystem: investors, accelerators, incubators, fellowships, grants, and global hubs powering next-gen Cell & Gene Therapy startups.
Scouts
Share promising startups in this sector and get rewarded if they raise. No prior track record needed.
Investors
Access qualified startups curated by Superscout across pre-seed to seed.
Supporters
Work at a company, lab, or city? Connect with builders in your space.
Cell and gene therapy encompasses the technologies that treat diseases by modifying patients' cells or delivering genetic material to correct or replace defective genes. CAR-T cell therapy (engineering a patient's immune cells to attack cancer) has produced breakthrough treatments: Kymriah and Yescarta deliver complete remission rates of 40-80% in certain blood cancers that had no effective treatment. Gene therapy using viral vectors (AAV, lentivirus) delivers functional copies of genes to correct single-gene disorders, with Zolgensma ($2.1 million per dose for spinal muscular atrophy) and Casgevy (the first CRISPR-based therapy for sickle cell disease) representing landmark approvals. The sector's primary challenge is manufacturing: each CAR-T treatment is manufactured individually from a patient's own cells, creating a production bottleneck that limits access and drives costs above $400,000 per treatment. Allogeneic (off-the-shelf) approaches that use donor cells rather than patient cells could solve the manufacturing challenge but face scientific hurdles around immune rejection.
